Compare XOS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOS | LEXX |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | Canada |
| Employees | 109 | 7 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 16.2M |
| IPO Year | N/A | N/A |
| Metric | XOS | LEXX |
|---|---|---|
| Price | $1.81 | $0.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.00 | $1.50 |
| AVG Volume (30 Days) | 27.3K | ★ 179.7K |
| Earning Date | 05-13-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.12 | N/A |
| Revenue Next Year | $10.49 | $601.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.46 |
| 52 Week High | $5.60 | $1.67 |
| Indicator | XOS | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 59.44 |
| Support Level | N/A | $0.80 |
| Resistance Level | $2.15 | $1.05 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 34.55 | 61.84 |
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.